SG/CALL/NOVO-NORDISK B/1100/0.1/21.03.25 | Market Closed - Bid/Ask 02:45:48 2024-05-21 EDT | Pre-market 02:47:59 | |||
| 0.9 EUR | -3.23% |
|
0.905 | +0.56% |
| Current month | -2.11% | ||
| 1 month | +13.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 0.9 | -3.23% |
| 24-05-20 | 0.93 | +4.49% |
| 24-05-17 | 0.89 | -6.32% |
| 24-05-16 | 0.95 | -3.06% |
| 24-05-15 | 0.98 | +2.08% |
Real-time Boerse Frankfurt Warrants
Last update May 21, 2024 at 02:45 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7ZJC |
| ISIN | DE000SW7ZJC0 |
| Date issued | 2024-03-20 |
| Strike | 1,100 kr |
| Maturity | 2025-03-21 (305 Days) |
| Parity | 10 : 1 |
| Emission price | 1.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.14 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.04 € |
| Spread % | 4.26% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
